Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

Every investor in Silence Therapeutics plc ( NASDAQ:SLN) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 44% to be precise, ...

Piper Sandler has reaffirmed its Overweight rating on shares of Context Therapeutics (NASDAQ: CNTX) with a consistent price target of $4.50. The firm's confidence is bolstered by... Piper Sandler ...

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...

Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

January 3, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...